Longitudinal characterization of biomarkers for spinal muscular atrophy-Reference-Cited by-同舟云学术

Longitudinal characterization of biomarkers for spinal muscular atrophy

Published:2017-04-11 Issue:5 Volume:4 Page:292-304
ISSN:2328-9503
Container-title:Annals of Clinical and Translational Neurology
language:en
Short-container-title:Ann Clin Transl Neurol

Author:

Bonati Ulrike¹²,Holiga Štefan³⁴,Hellbach Nicole³,Risterucci Céline³,Bergauer Tobias³,Tang Wakana⁵,Hafner Patricia¹²⁶,Thoeni Alain⁷⁸,Bieri Oliver⁸,Gerlach Irene³,Marquet Anne³,Khwaja Omar³,Sambataro Fabio³,Bertolino Alessandro³,Dukart Juergen³,Fischmann Arne⁸⁹,Fischer Dirk¹²,Czech Christian³

Affiliation:

1. Division of Neuropediatrics; University of Basel Children's Hospital; Spitalstrasse 33 4056 Basel Switzerland

2. Department of Neurology; University of Basel Hospital; Petersgraben 4 4031 Basel Switzerland

3. Roche Pharma and Early Development; Neuroscience, Ophthalmology and Rare Diseases; Roche Innovation Center Basel; F. Hoffmann-La Roche Ltd; Grenzacherstrasse 124 4070 Basel Switzerland

4. Max Planck Institute for Human Cognitive and Brain Sciences; Stephanstr. 1A 04103 Leipzig Germany

5. Roche Molecular Diagnostics; Research Genomics & Oncology; Roche Molecular Systems Inc.; 4300 Hacienda Dr Pleasanton 94588 California USA

6. University Clinics of Internal Medicine; Kantonsspital Baselland; Bruderholz 4101 Switzerland

7. MIAC AG; c/o University of Basel Hospital; Mittlere-Strasse 83 4031 Basel Switzerland

8. Department of Radiology; University of Basel Hospital; Petersgraben 4 4031 Basel Switzerland

9. Hirslanden Klinik St. Anna; St. Anna-Strasse 32 6006 Luzern Switzerland

Funder

F. Hoffmann-La Roche

Publisher

Wiley

Subject

Neurology (clinical),General Neuroscience

Reference44 articles.

1. Spinal muscular atrophy;Lunn;Lancet,2008

2. Childhood spinal muscular atrophy: controversies and challenges;Mercuri;Lancet Neurol,2012

3. Spinal muscular atrophy: a motor neuron disorder or a multi-organ disease?;Shababi;J Anat,2014

4. Motor neuron disease. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy;Naryshkin;Science,2014

5. Advances in therapeutic development for spinal muscular atrophy;Howell;Future Med Chem,2014

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of circulating biomarkers in spinal muscular atrophy: insights from a new treatment era;Frontiers in Neurology;2023-11-13

2. Digital measures of respiratory and upper limb function in spinal muscular atrophy: design, feasibility, reliability, and preliminary validity of a smartphone sensor-based assessment suite;Neuromuscular Disorders;2023-11

3. Molecular Biomarkers for the Diagnosis, Prognosis, and Pharmacodynamics of Spinal Muscular Atrophy;Journal of Clinical Medicine;2023-08-01

4. Multi-omics profiling of CSF from spinal muscular atrophy type 3 patients after nusinersen treatment: a 2-year follow-up multicenter retrospective study;Cellular and Molecular Life Sciences;2023-08

5. Biomarkers in 5q-associated spinal muscular atrophy—a narrative review;Journal of Neurology;2023-06-08